DALLAS, Dec. 18, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring deCODE Genetics Inc (Nasdaq:DCGN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/DCGN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
deCODE Genetics Inc. (DCGN) engages in the research and commercialization of DNA-based tests and genome scans to reveal genetic risk factors of disease, including cardiovascular, cancer and diabetes. The Company licenses its tests and intellectual rights to big pharmaceuticals and research institutions, globally. On November 16, 2009, the Company filed Chapter 11 in the District of Columbia.
In the report, the analyst notes:
"According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012, while advisory firm Decision Resources expects new product launches will drive an increase in the coronary artery disease market by approximately $4.6 billion through 2017. Moreover, a new report released by Pharmacor entitled 'Coronary Heart Disease' states that sales of coronary therapies to the United States and other developed nations of Europe, UK and Japan will increase to $19.4 billion in 2017.
"On December 16, the Company announced that its team of scientists discovered mutations in five genes related to diseases identified as inherited by a particular parent. For example, the team found that genes associated with diabetes protects against the disease if inherited by the mother, but increases the risk for the disease if inherited from the father."
To read the entire report visit: http://www.beaconequity.com/i/DCGN
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.